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Metformin is themost widely prescribed drug to lower glucose in type II diabetics, yet itsmechanismof action
remains controversial. A new study reveals that metformin inhibits mitochondrial glycerol-3-phosphate
dehydrogenase, triggering reduction of the cytosolic NADH/NAD+ pool and impaired utilization of redox-
dependent substrates for gluconeogenesis (Madiraju et al., 2014).Biguanides, including metformin, have
been used for over 50 years to treat dia-
betes and have shown promise as cancer
therapeutics. Central to metformin’s ef-
fects is a dramatic lowering of hepatic
glucose output, yet its precise mecha-
nism of action has remained enigmatic.
Metformin inhibits complex I of the elec-
tron transport chain, which was proposed
to decrease the ATP/ADP ratio, shifting
the equilibrium of the phosphoglycerate
kinase reaction to disfavor glucose syn-
thesis (Owen et al., 2000). Subsequently,
it was suggested that metformin acts via
the energy sensor AMP-activated protein
kinase (AMPK) (Zhou et al., 2001).
Although several studies have since indi-
cated that metformin can function inde-
pendently from AMPK (Foretz et al.,
2010; Miller et al., 2013), recent reports
have argued that AMPK is indeed
required for some effects of the drug (Full-
erton et al., 2013). In addition, metformin-
induced AMP accumulation directly in-
hibits adenylate cyclase, blocking the
induction of gluconeogenesis byglucagon
(Miller et al., 2013). A new report now
shows that metformin shifts the NADH/
NAD+ ratio in liver to inhibit glucose pro-
duction independently of energy charge
via a novel direct target, mitochon-
drial glycerol-3-phosphate dehydroge-
nase (mGPD) (Madiraju et al., 2014).
Mammalian tissues contain at least two
pools of NADH and NAD+, nucleocyto-
solic and mitochondrial. To study effects
of metformin in the two compartments,
Madiraju et al. measured hepatic lactate
and pyruvate, which equilibrate with cyto-
solic NADH/NAD+ (via lactate dehydroge-
nase), as well as b-hydroxybutyrate andacetoacetate, which equilibrate withmito-
chondrial NADH/NAD+ (via b-hydroxybu-
tyrate dehydrogenase). Cytosolic NADH/
NAD+ ratio increased in the livers of met-
formin-treated animals while the mito-
chondrial NADH/NAD+ ratio decreased.
This is surprising given prior reports that
biguanides increase both cytoplasmic
and mitochondrial NADH/NAD+ ratios,
consistent with inhibition of complex I
(Owen et al., 2000). Opposing shifts would
not be expected to arise due to the activity
of redox shuttles—biochemical reactions
that transfer electrons from cytosolic
NADH into the mitochondria—suggesting
that shuttle systems themselves might be
impaired (Madiraju et al., 2014). Accord-
ingly, Madiraju et al. discovered that
therapeutic concentrations of metformin
inhibited a key enzyme in the glycero-
phosphate shuttle, mGPD, by 50%.
mGPD knockdown in vivo recapitulated
the effects of metformin treatment, and
metformin had no further effect in these
animals. It was concluded that metformin
works by halting the glycerophosphate
shuttle, directly blocking gluconeogen-
esis from glycerol and preventing clear-
ance of cytosolic NADH, leading to a
higher NADH/NAD+ ratio that impairs
glucose production from lactate.
A central question raised by this work is
whether flux through the glycerophos-
phate shuttle is high enough to cause
the observed redox shifts. An alternative
redox shuttle, the malate-aspartate
shuttle, is operative in liver, although its
activity is diminished during increased py-
ruvate carboxylate flux (i.e., gluconeo-
genesis) (Kunz and Davis, 1991). Even
so, disruption of the malate-aspartateCell Metabolism 2shuttle in mice lowers fasting glycemia
and increases the cytosolic NADH/NAD+
ratio in the liver, whereas disrupting the
glycerophosphate shuttle has no effect
on glycemia (Saheki et al., 2007). More-
over, reliance on the malate-aspartate
shuttle appears to be higher still in hu-
mans than in mice (Saheki et al., 2007). In-
hibition of complex I might increase the
importance of the glycerophosphate
shuttle, since the malate-aspartate shut-
tle requires mitochondrial membrane
potential. It is also unclear how much
flux through shuttles is necessary during
gluconeogenesis from lactate, since
NADH produced by lactate dehydroge-
nase is subsequently consumed by
GAPDH. This question is underscored by
the finding that knocking down cGPD,
an obligate component of the glycero-
phosphate shuttle, produces only a
muted effect on redox status as com-
pared to mGPD and does not suppress
glucose production. In considering mito-
chondrial redox status, even when triglyc-
erides are used as the sole respiratory
substrate, electrons donated by the glyc-
erophosphate shuttle account for only
0.5% of ATP production. Thus, the loss
of these electrons would be unlikely to ac-
count for a measureable change in mito-
chondrial NADH/NAD+ ratio.
To account for the cytosolic redox shift,
we propose an alternative interpretation:
the increase in cytosolic NADH may not
reflect halting of glycerophosphate shut-
tle, but rather production of NADH by
cGPD running in the opposite direction
(Figure 1). The effects of metformin would
then be blocked in the absence of cGPD
and depend on the presence of glycerol0, August 5, 2014 ª2014 Elsevier Inc. 197
AB
Figure 1. Metformin Inhibits Mitochondrial Glycerol-3-Phosphate Dehydrogenase (mGPD), Raising Cytosolic NADH and Blocking
Incorporation of Lactate into Glucose
(A) If mGPD functions predominantly in the glycerophosphate shuttle (red box), inhibition by metformin will be expected to slow the removal of NADH, leading to
an increase in the cytosolic NADH/NAD+ ratio that feeds back on lactate dehydrogenase (LDH).
(B) If flux from glycerol to glucose is significant (blue box), inhibition of mGPD by metformin may lead to accumulation of glycerol-3-phosphate (G-3-P) such that
oxidation to dihydroxyacetone phosphate (DHAP) by cGPD becomes favorable.WhereasmGPD catalyzes this reaction by donating electrons directly to the elec-
tron transport chain, cGPD would concomitantly produce NADH, increasing the cytosolic NADH/NAD+ ratio, which would feed back on LDH. Note that the glyc-
erophosphate shuttle catalyzes the net transfer of electrons from NADH to ubiquinone (Q) in the electron transport chain with regeneration of the intermediate
dihydroxyacetone phosphate (DHAP) andG-3-P pools. Reverse flux through cGPDwould not be expected in the absence of an external source of G-3-P or oxida-
tion of the cytosolic NADH pool.
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latter prediction might be related to the
lack of metformin effects in mice with
constitutively active acetyl-CoA carbox-
ylase, since impaired fatty acid oxidation
and enhanced synthesis would be ex-
pected to lower endogenous glycerol pro-
duction (Fullerton et al., 2013).
Another critical question is whether
mechanisms based on energy charge
can be excluded. To address this, Madir-
aju et al. measured ATP, ADP, and AMP
to argue that clinically relevant concen-
trations of metformin do not affect energy
charge, despite activating AMPK. In sup-
port, they cite data showing activation of
AMPK in the absence of changes in AMP
(Madiraju et al., 2014). However, Hardie
and colleagues recently reported that
even when it was impossible to detect
an increase in cellular AMP, activation of
AMPK still depended on AMP binding
(Hawley et al., 2010). Therefore, the in-
crease in phosphorylation of AMPK and
its substrate ACC in the chronic in vivo
studies in Madiraju et al. may be indica-
tive of an AMP increase. Madiraju et al.198 Cell Metabolism 20, August 5, 2014 ª201also observed reduced phosphorylation
of CREB, the major PKA substrate, in
response to chronic metformin. Given
the difficulties of detecting small changes
in cAMP in vivo, the decrease in phos-
pho-CREB likely reflects a reduction in
cAMP level, possibly due to AMP-depen-
dent inhibition of adenylate cyclase
(Miller et al., 2013). Thus, the most
harmonious interpretation of the Madiraju
et al. data is that there are at least two
complementary mechanisms of metfor-
min action.
A final consideration is time depen-
dency in the action of metformin. Metfor-
min does not cross membranes effi-
ciently, but concentrates slowly in cells
and mitochondria by virtue of its positive
charge interacting with polarized mem-
branes; this is reflected by a lag to the
onset of effects in many assays and
increased efficacy of low doses after pro-
longed incubation (Davidoff, 1971; Miller
et al., 2013; Owen et al., 2000). Depen-
dence on membrane potential provides
an attractive mechanism for metformin’s
effects to be self-limiting via inhibition of4 Elsevier Inc.complex I, consistent with its excellent
safety profile. Importantly, the in vitro ex-
periments in Madiraju et al. that excluded
a direct effect of metformin on complex I
involved only acute treatment. It is also
notable that while phenformin inhibits
glucose production and complex I activity
more effectively than does metformin, it
does not appear to be more efficacious
in inhibiting mGPD. Nevertheless, the
observation of Madiraju et al. that mito-
chondrial NADH/NAD+ ratio is oxidized
by metformin is a key argument against
the involvement of complex I inhibition.
Importantly, Madiraju et al. administered
metformin intravenously, which probably
led to lower hepatic levels than when the
drug is given orally, as done therapeuti-
cally or in previous studies where the
opposite result was obtained (Owen
et al., 2000).
Inhibition of mGPD is a new and poten-
tially crucial piece of the puzzle as to how
metformin exerts its beneficial effects on
glucose homeostasis. A better under-
standing of how the most widely pre-
scribed glucose-lowering agent works
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Previewscould lead to improved outcomes for mil-
lions of diabetics worldwide.
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The breakdown of cellular fat stores fuels energy production and multiple anabolic processes. Albert et al.
(2014) demonstrate that the lack of hormone-sensitive lipase, a member of the enzyme trio that catabolizes
fat, has pronounced effects on lipid metabolism, glucose homeostasis, and cell signaling in humans.Adipose tissue is the body’s largest
reservoir of energy and a major source
of metabolic fuel. In periods of food sup-
ply, excess nutrients are stored as triglyc-
erides (TGs) in white adipose tissue,
whereas during energy demand, TGs
are hydrolyzed to release nonesterified
fatty acids (FAs) into the bloodstream.
Nonadipose tissues, in turn, utilize FAs
effectively for energy production, mem-
brane lipid synthesis, or lipid signaling.
The transient storage of FAs as TGs in
adipose tissue is also important to pro-
tect the organism from harmful ‘‘lipo-
toxic’’ effects of excessive intracellular
FA concentrations including ectopic lipid
deposition in liver and skeletal muscle
and the development of insulin resis-
tance. Thus, alterations in adipose tissue
TG metabolism have profound effects on
whole-body homeostasis. The catabolic
pathway hydrolyzing TGs is called lipol-
ysis. It is an exquisitely controlled pro-
cess involving a variety of cell-surface re-ceptors, neurotransmitters, hormones,
and paracrine factors that result in the
sequential enzymatic hydrolysis of three
FA-glycerol ester bonds (Lafontan and
Langin, 2009; Zechner et al., 2012). The
major enzymes working in a step-wise
fashion are adipose triglyceride lipase
(ATGL), hormone-sensitive lipase (HSL),
and monoglyceride lipase (MGL). Mouse
and human studies identified ATGL as
the major TG lipase, while HSL and
MGL predominantly hydrolyze diglycer-
ides (DGs) and monoglycerides (MGs),
respectively. HSL has a broader sub-
strate specificity than the other enzymes
additionally hydrolyzing TGs, MGs, retinyl
esters (REs), and cholesterol esters
(CEs). The phenotypes observed in
lipase-deficient mouse models are
consistent with these enzymatic activ-
ities. ATGL-deficient mice accumulate
TGs in multiple tissues with the highest
fat content in oxidative tissues such as
brown adipose tissue, cardiac muscle,and kidney. Loss of ATGL in cardiac mus-
cle results in severe cardiomyopathy,
heart failure, and premature death in
ATGL knockout mice at the age of
4 months. In humans, ATGL deficiency
causes neutral lipid storage disease with
myopathy (NLSDM) (Fischer et al.,
2007), a condition similar to the knockout
phenotypes observed in mice. Clinical
manifestations start later and are more
variable in humans than in mice, but
many patients also develop a severe
cardiomyopathy requiring heart trans-
plantation to prevent cardiac death.
Despite a very detailed knowledge
of the biochemical and physiological
functions of HSL, a clear link between
HSL deficiency and human disease was
missing. Now, Albert et al. (2014) report
in the June 12 issue of the New England
Journal of Medicine the first clinical
characterization of individuals with a
frameshift mutation in the LIPE gene
encoding HSL (Albert et al., 2014).0, August 5, 2014 ª2014 Elsevier Inc. 199
